Invus logo

Invus

Crunchbase
Pitchbook
Crunchbase

Deals on record

13

Common Fundraising Type

Series A

Leyden Labs logo
Leyden Labs

Mucosal Protection

ClavystBio logo
Qiming Venture Partners logo
Polaris Partners logo
GV logo
Casdin Capital logo
F-Prime Capital logo
Invus logo
Byers Capital logo

Leyden Labs develops non-vaccine intranasal antibody treatments to protect against respiratory viruses like influenza and coronaviruses.

Equity
$70M
01/09/2025
Article
Coave Therapeutics logo
Coave Therapeutics

Genetic medicines

UI Investissement logo
Turenne Capital logo
Seroba Life Sciences logo
Omnes Capital logo
Novo Holdings logo
Kurma Partners logo
Invus logo
Fund+ logo

Coave Therapeutics develops genetic medicines using their ALIGATER™ platform to enhance treatment for CNS, neuromuscular, and eye diseases.

Series A
$33M
01/09/2025
Article
Tasca Therapeutics logo
Tasca Therapeutics

Biotechnology

Cure Ventures logo
Regeneron Ventures logo
Invus Group logo

Tasca Therapeutics is a biotechnology company focused on developing small molecule inhibitors for oncology using a unique drug discovery platform.

Series A
$52M
12/10/2024
Article
Zenflow logo
Zenflow

Medical device

Medical Technology Venture Partners logo
Invus Opportunities logo
F-Prime Capital logo
Cook Medical logo

Zenflow, Inc. develops minimally invasive medical devices for treating urinary obstruction caused by benign prostatic hyperplasia (BPH).

Series C
$24M
11/18/2024
Article
Agomab logo
Agomab

Biotech

Sanofi logo
Invus logo

Agomab Therapeutics is a Belgian biotech company developing novel treatments for fibrosis, with a pipeline of growth factor targeting antibodies and small molecule compounds.

Series D
$88.8M
10/25/2024
Article
Vinted logo
Vinted

Online marketplace

TPG logo
Moore Strategic Ventures logo
Manhattan Venture Partners logo
Invus Opportunities logo
Hedosophia logo
FJ Labs logo
Baillie Gifford logo

Vinted is an online marketplace that allows users to buy, sell, and exchange second-hand fashion and electronics.

Equity
$366.6M
10/24/2024
Article
Seaport Therapeutics logo
Seaport Therapeutics

Neuropsychiatric

General Atlantic logo
T. Rowe Price Associates logo
Sofinnova Investments logo
Third Rock Ventures logo
PureTech Health logo
Invus logo
Goldman Sachs Alternatives logo
Foresite Capital logo

Seaport Therapeutics develops neuropsychiatric medicines using its Glyph technology platform to enhance oral bioavailability and reduce side effects, with a focus on treating depression, anxiety, and other disorders.

Series B
$225M
10/22/2024
Article
City Therapeutics logo
City Therapeutics

Biopharmaceutical

ARCH Venture Partners logo
Regeneron Ventures logo
Rock Springs Capital logo
Slate Path Capital logo
Invus logo
Fidelity Management & Research Company logo
AN Ventures logo

City Therapeutics is a biopharmaceutical company focused on developing RNA interference-based medicines using engineered small interfering RNAs to target a broad range of diseases.

Series A
$135M
10/08/2024
Article

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Series B
$115M
10/02/2024
Article
Engine Biosciences logo
Engine Biosciences

Precision Oncology

ClavystBio logo
Polaris Partners logo
SEEDS Capital logo
Invus logo
EDBI logo
Coronet Ventures logo

Engine Biosciences uses machine learning and high-throughput biology to develop precision oncology medicines, and with their recent funding, they plan to advance their biomarker and target discoveries toward the clinic through internal development, collaborations, and partnerships.

Series A
$27M
10/31/2023
Article

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Series A
$92M
10/26/2023
Article
PayJoy logo
PayJoy

Fintech

Warburg Pincus logo
Union Square Ventures logo
Invus logo
Greylock logo
Citi Ventures logo

PayJoy is a San Francisco-based public benefit corporation that provides smartphone-based finance solutions to underserved populations in emerging markets, using its patented mobile security technology to extend credit.

Hybrid C
$360M
09/06/2023
Article